Skip to main content
Top
Published in: PharmacoEconomics 2/2014

01-02-2014 | Original Research Article

The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer

Authors: J. Jayasekera, E. Onukwugha, K. Bikov, C. D. Mullins, B. Seal, A. Hussain

Published in: PharmacoEconomics | Issue 2/2014

Login to get access

Abstract

Background and Objective

Advanced prostate cancer patients with bone metastasis are predisposed to skeletal complications termed skeletal-related events (SREs). There is limited information available on Medicare costs associated with treating SREs. The objective of this study was to ascertain SRE-related costs among older men with metastatic prostate cancer in the US.

Methods

We analysed patients aged 66 years or older who were diagnosed with incident stage IV (M1) prostate cancer between 2000 and 2007 from the linked Surveillance, Epidemiology and End Results (SEER)–Medicare dataset. A propensity score for the incidence of an SRE was estimated using a logistic regression model including demographic and clinical baseline variables. Patients with SREs (cases) were matched to patients without SREs (controls) based on the propensity score, length of follow-up (i.e. date of prostate cancer diagnosis to last date of observation) and death. Health resource utilization cost differences between cases and controls over time were compared using generalized linear models. Healthcare costs were examined by type of SRE (pathological fracture only, pathological fracture with concurrent surgery, spinal cord compression only, spinal cord compression with concurrent surgery, and bone surgery only) and by source of care (inpatient, physician/non-institutional provider, skilled nursing facility, outpatient and hospice). All costs were adjusted to 2009 US dollars, using the medical care component of the Consumer Price Index.

Results

Application of the inclusion criteria resulted in 1,131 metastatic prostate cancer patients with SREs and 6,067 patients without SREs during follow-up. The average age of the sample was 79 years, and 14 % were African American. A total of 928 patients with SREs were matched to 928 patients without SREs. The average health care utilization cost of patients with SREs was US$29,696 (95 % confidence interval [CI] US$24,730–US$34,662) higher than that of the controls. The most expensive SRE group was spinal cord compression with concurrent surgery (US$82,868: 95 % CI US$67,472–US$98,264) followed by bone surgery only (US$37,496: 95 % CI US$29,684–US$45,308), pathological fracture with concurrent surgery (US$34,169: 95 % CI US$25,837–US$ 42,501), spinal cord compression only (US$25,793: 95 % CI US$20,933–US$30,653) and pathological fracture only (US$14,649: 95 % CI US$6,537–US$22,761). The largest cost difference by source of care was observed for hospitalizations (p < 0.01).

Conclusion

Metastatic prostate cancer patients with SREs incur higher costs compared to similar patients without SREs. SRE costs among older stage IV (M1) prostate cancer patients vary by SRE type, with spinal cord compression and concurrent surgery costing at least twice as much as other SREs.
Appendix
Available only for authorised users
Footnotes
1
Total annual costs include the sum of the total monthly costs of inpatient, physician/non-institutional provider, skilled nursing facility, outpatient, home health and hospice care, and durable medical equipment records, up to 12 months in the pre and post periods.
 
2
Total annual pre–post cost difference (up to 12 months in the pre and post periods) = (total annual health care utilization costs in the post period) − (total annual health care utilization costs in the pre period).
 
3
Total annual pre–post cost difference (up to 12 months in the pre and post periods) = (total annual health care utilization costs in the post period) − (total annual health care utilization costs in the pre period).
 
Literature
1.
go back to reference Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manage Care Pharm. 2010;16(9):693–702 pii: 2010(16)9:693-702. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manage Care Pharm. 2010;16(9):693–702 pii: 2010(16)9:693-702.
2.
go back to reference Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care. 2008;14(5):317–22 pii: 10307. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care. 2008;14(5):317–22 pii: 10307.
3.
4.
go back to reference Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(1):23–7. doi:10.1038/pcan.2012.42.PubMedCrossRef Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(1):23–7. doi:10.​1038/​pcan.​2012.​42.PubMedCrossRef
5.
go back to reference Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579–84. doi:10.1093/annonc/mdi122.PubMedCrossRef Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579–84. doi:10.​1093/​annonc/​mdi122.PubMedCrossRef
6.
go back to reference Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011;14(2):177–83. doi:10.1038/pcan.2011.7.PubMedCrossRef Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011;14(2):177–83. doi:10.​1038/​pcan.​2011.​7.PubMedCrossRef
11.
14.
go back to reference Bergstralh EJ, Kosanke JL. Computerized matching of controls. Section of Biostatistics Technical Report 56. Rochester: Mayo Foundation; 1995. Bergstralh EJ, Kosanke JL. Computerized matching of controls. Section of Biostatistics Technical Report 56. Rochester: Mayo Foundation; 1995.
16.
go back to reference Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–7.PubMedCrossRef Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–7.PubMedCrossRef
17.
go back to reference Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health. 2011;14(4):499–505. doi:10.1016/j.jval.2010.11.014.PubMedCrossRef Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health. 2011;14(4):499–505. doi:10.​1016/​j.​jval.​2010.​11.​014.PubMedCrossRef
18.
go back to reference Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43(3):226–32.PubMedCrossRef Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43(3):226–32.PubMedCrossRef
20.
go back to reference Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419–34.PubMedCrossRef Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419–34.PubMedCrossRef
21.
go back to reference Gray AM, Clarke PM, Wolstenholme JL. Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press Inc.; 2010. p. 157–8. Gray AM, Clarke PM, Wolstenholme JL. Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press Inc.; 2010. p. 157–8.
22.
go back to reference Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.1097/MLR.0b013e318277eb6f.PubMed Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.​1097/​MLR.​0b013e318277eb6f​.PubMed
24.
go back to reference Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82. doi:10.1093/jnci/djh141.PubMedCrossRef Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82. doi:10.​1093/​jnci/​djh141.PubMedCrossRef
25.
go back to reference Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962–9. doi:10.1002/cncr.11571.PubMedCrossRef Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962–9. doi:10.​1002/​cncr.​11571.PubMedCrossRef
26.
go back to reference Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71. doi:10.1200/jco.2008.19.2146.PubMedCrossRef Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71. doi:10.​1200/​jco.​2008.​19.​2146.PubMedCrossRef
27.
go back to reference Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press Inc.; 2007. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press Inc.; 2007.
28.
go back to reference McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman & Hall/CRC; 1989.CrossRef McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman & Hall/CRC; 1989.CrossRef
Metadata
Title
The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer
Authors
J. Jayasekera
E. Onukwugha
K. Bikov
C. D. Mullins
B. Seal
A. Hussain
Publication date
01-02-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 2/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0121-y

Other articles of this Issue 2/2014

PharmacoEconomics 2/2014 Go to the issue